Stem cell

Israel-based clinical-stage biopharmaceutical firm BioLineRx has received notice from the US Food & Drug Administration (FDA) confirming an Orphan Drug Designation for BL-8040 as a treatment for stem cell mobilisation.

The FDA has previously granted orphan drug designation to BL-8040 for the treatment for acute myeloid leukemia (AML).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

BL-8040 is a clinical-stage drug candidate indicated for the treatment of AML, as well as other haematological indications.

The orphan drug status was granted for use of BL-8040, in combination with granulocyte colony-stimulating factor (G-CSF), to mobilise human stem cells from the bone marrow to the peripheral blood for collection for autologous or allogeneic transplantation.

"This is in line with our 2014 development plan for BL-8040, which includes clinical studies for both AML and stem cell mobilisation."

BioLineRx chief executive officer Kinneret Savitsky said: "This is in line with our 2014 development plan for BL-8040, which includes clinical studies for both AML and stem cell mobilisation."

See Also:

In the Phase I/II trial carried out in multiple myeloma patients, BL-8040 has already shown to be highly effective in mobilising stem cells in combination with G-CSF.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Initial results of BL-8040’s Phase II trial for AML patients show that, BL-8040 on a stand-alone basis triggers substantial mobilisation of cancer cells from the bone marrow to the peripheral blood.

The company expects to release the results of the clinical trials in both indications in the second half of 2014.

BL-8040 is a short peptide that functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in tumor progression, angiogenesis, metastasis and cell survival.

Image: Stem cells are mobilized from the bone marrow using granulocyte colony-stimulating factor (G-CSF). Photo: courtesy of freedigitalphotos.net.